Abstract
We read with interest the article by Morris et al. [1][1] evaluating the role of sildenafil therapy for thalassemia patients with Doppler-defined risk for pulmonary hypertension (PH). Here we reflect on the Authors’ findings and highlight our experience with sildenafil therapy in a similar patient
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.